Ketamine molecule:

Image from PubChem

Ketamine Clinical Trials

A Phase 1 Pharmacokinetics and Pharmacodynamics of Ketamine Transdermal Drug Delivery System in Subjects With Sub-Optimally Responsive Major Depressive Disorders

To see complete record on, please visit this link

Id: NCT03721900

Organisation Name: Shenox Pharmaceuticals, LLC

Overal Status: Unknown status

Start Date: December 28, 2018

Last Update: April 25, 2019

Lead Sponsor: Shenox Pharmaceuticals, LLC

Brief Summary: The purpose of this study is to measure the amount of ketamine in blood over time in subjects diagnosed with Major Depressive Disorder (MDD) and explore the anti-depressive effects of ketamine delivered by transdermal patch.

  • Major Depressive Disorder

Total execution time in seconds: 0.26297688484192